title: Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers.
abstract: OBJECTIVE
  To compare rabeprazole (RPZ; 10 mg) with Lansoprazole orally disintegrating tablets (LPZ; 30 mg OD) in terms of antisecretory activity and blood drug concentration after a single dose.
  
  
  METHODS
  Eight H pylori -negative cytochrome P450 (CYP) 2C19 extensive metabolizers were assigned to receive a single oral dose of RPZ 10 mg or LPZ 30 mg OD. Twelve hour intragastric pH monitoring was performed on the day of treatment. Blood samples were also collected after the administration of each drug.
  
  
  RESULTS
  LPZ 30 mg OD induced a significantly earlier rise in blood drug concentration than RPZ 10 mg; consequently, LPZ 30 mg OD induced a significantly earlier rise in median pH in the third and fourth hours of the study.
  
  
  CONCLUSIONS
  In H pylori-negative CYP2C19 extensive metabolizers, LPZ 30 mg OD induced a significantly faster inhibition of gastric acid secretion than RPZ 10 mg.
authors.affiliation: Division of Gastroenterology Tohoku University graduate school of medicine, 1-1 Seiryou-Machi, Aobaku, Sendai 9808574, Japan. hatsushi@f2.dion.ne.jp
authors.forename: Hatsushi
authors.initials: H
authors.lastname: Yamagishi
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Koike
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ohara
authors.forename: Toru
authors.initials: T
authors.lastname: Horii
authors.forename: Ryousuke
authors.initials: R
authors.lastname: Kikuchi
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Abe
authors.forename: Katsunori
authors.initials: K
authors.lastname: Iijima
authors.forename: Akira
authors.initials: A
authors.lastname: Imatani
authors.forename: Kaori
authors.initials: K
authors.lastname: Suzuki
authors.forename: Takanori
authors.initials: T
authors.lastname: Hishinuma
authors.forename: Junichi
authors.initials: J
authors.lastname: Goto
authors.forename: Tooru
authors.initials: T
authors.lastname: Shimosegawa
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000494:pharmacology*; D000284:Administration, Oral; D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D065731:Cytochrome P-450 CYP2C19; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism*; D005838:Genotype; D016480:Helicobacter pylori / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D064750:Rabeprazole
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D064750:Rabeprazole; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19